The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
The directors are being very cautious because of the dispute. Should they misuse the money, they could be held responsible for it. But I believe that a good acquisition would bring value to the company, and could count as a tangible asset in the event of losing the dispute.
However, they would have to buy in cash, without offering shares because who would take shares knowing they could be worthless if the dispute is lost?
Not very concerning thankfully, it seems the virus is still not adapted to humans so no human to human transmission. But it is the largest outbreak in history, there's a big market for veterinary tests here it seems
From that CV page (and I don't know anything about this guy, so I'm not vouching for him) seems to have studied biology and health sciences at university level, enough to understand mRNA
However, how could Novacyt benefit from what's said on the video? unless vaccines are retired from the market, I don't see it
PI100, don't be surprised, I read your post this morning about value in Jan 2020 and being 4x, if also, by your other post, non covid revenue is half of 2019 then we can conclude fair price is 1/8 of what we have today. Expect another 80% drop?
Hi P100, I agree with what you have said of the board but without a CEO, I don't expect any big strategic decisions to be made. Do you know where to short this AIM stock? If that's even possible on a low cap like this, I think it would be worth exploring so you could cover your losses